What this trial means for you
This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Retatrutide, Placebo for obesity, overweight.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * Have a body mass index (BMI) of: * ≥30 kilogram per square meter (kg/m2) OR * ≥27 kg/m2 with at least one of the following weight-related conditions: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease * Have at least one unsuccessful attempt to lose weight by dieting Exclusion Criteria: * Have a self-reported change in body weight \>5 kg (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have type 1 diabetes or type 2 diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening * acute myocardial infarction * cerebrovascular accident (stroke) * hospitalization for unstable angina, or * hospitalization due to congestive heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening
Study sites by state
California
- Artemis Institute for Clinical Research — Riverside
Florida
- JEM Research Institute — Atlantis
- Headlands Research Orlando — Orlando
- Care Access - Tamarac — Tamarac
Illinois
- Care Access - Arlington Heights — Arlington Heights
Kentucky
- L-MARC Research Center — Louisville
Louisiana
- IMA Clinical Research Monroe - Armand — Monroe
Maryland
- Pharmasite Research, Inc. — Baltimore
Missouri
- Clinical Research Professionals — Chesterfield
- Clinvest Headlands Llc — Springfield
New Jersey
- IMA Clinical Research Warren — Warren Township
New York
- IMA Clinical Research Manhattan — New York
North Carolina
- Trial Management Associates - Wilmington - Floral Parkway — Wilmington
Texas
- Cedar Health Research — Dallas
- Headlands Research-El Paso — El Paso
- Cedar Health Research - Euless — Euless
- Cedar Health Research - Fort Worth — Fort Worth
- Care Access - Houston — Houston
- IMA Clinical Research San Antonio — San Antonio
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)